Hoth Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Hoth Therapeutics zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	14.4%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Sep 08

Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Hoth Therapeutics (NASDAQ: HOTH) is emerging as one of the most intriguing small-cap biotech stories on the market. With a market capitalization of just ~$16 million, the company is combining tangible clinical success with cutting-edge AI tools, creating a potentially asymmetric investment opportunity.

Analyseartikel • Sep 05

Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

This week’s picks cover: Why Venmo and merchant solutions are driving PayPal’s upside potential, how IREN’s pivot from Bitcoin mining to AI infrastructure is adding value, and how Cadeler’s fleet expansion rides offshore wind growth.

Narrativ-Update • Sep 05

100% Patient Improvement in trial puts this $16M Biotech on the radar

Strengthening Pipeline with Breakthrough AI Hoth Therapeutics (NASDAQ: HOTH) is layering cutting-edge technology on top of its strong clinical momentum. Already known for its standout Phase 2 trial results (100% patient improvement with HT-001 cancer rash trial), Hoth is now integrating Lantern Pharma’s PredictBBB.ai platform , an AI tool with 94% accuracy in predicting whether drugs can cross the blood–brain barrier (BBB).

Neues Narrativ • Sep 01

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

Seeking Alpha • Sep 20

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Hoth Therapeutics (NASDAQ:HOTH) said on Tuesday it had signed an agreement with Altasciences to develop and manufacture the HT-TBI drug product formulation for the treatment and/or prevention of secondary brain injury. HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel. "We are leveraging Altasciences' expertise to develop and manufacture novel parenteral formulations to achieve a formulation that requires no preparation or special storage requirements to ensure HT-TBI can be used anywhere in the field at the time a head injury or stroke occurs," the company said.

Seeking Alpha • Jun 29

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Nasdaq has granted Hoth Therapeutics (NASDAQ:HOTH) an additional 180-days or until December 26, 2022 to regain compliance with minimum $1.00 closing bid price per share requirement. In a letter dated December 30, 2021, the company was notified that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days and it no longer meets the minimum bid price requirements. The company having provided written notice of its intention to cure the deficiency during the Additional Compliance Period, including by effecting a reverse stock split, if necessary. If the company does not comply with the minimum bid price requirement during the 180-day grace period than its shares are subject to delisting. Shares plunged around 72% over a period of one year.

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Hoth Therapeutics jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:HOTH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2026	N/A	-12	-10	-10	N/A
12/31/2025	N/A	-12	-10	-10	N/A
9/30/2025	N/A	-12	-10	-10	N/A
6/30/2025	N/A	-10	-9	-9	N/A
3/31/2025	N/A	-10	-8	-8	N/A
12/31/2024	N/A	-8	-7	-7	N/A
9/30/2024	N/A	-8	-8	-8	N/A
6/30/2024	N/A	-8	-8	-8	N/A
3/31/2024	N/A	-8	-8	-8	N/A
12/31/2023	N/A	-8	-8	-8	N/A
9/30/2023	N/A	-10	-8	-8	N/A
6/30/2023	N/A	-10	-9	-9	N/A
3/31/2023	N/A	-11	-9	-9	N/A
12/31/2022	N/A	-11	-9	-9	N/A
9/30/2022	N/A	-11	-11	-11	N/A
6/30/2022	N/A	-12	-11	-11	N/A
3/31/2022	N/A	-13	-12	-12	N/A
12/31/2021	N/A	-14	-12	-12	N/A
9/30/2021	N/A	-12	-9	-9	N/A
6/30/2021	N/A	-10	-8	-8	N/A
3/31/2021	N/A	-10	-7	-7	N/A
12/31/2020	N/A	-7	-6	-6	N/A
9/30/2020	N/A	-10	-7	-7	N/A
6/30/2020	N/A	-10	-7	-7	N/A
3/31/2020	N/A	-9	-6	-6	N/A
12/31/2019	N/A	-8	N/A	-5	N/A
9/30/2019	N/A	-4	N/A	-4	N/A
6/30/2019	N/A	-3	N/A	-3	N/A
3/31/2019	N/A	-3	N/A	-3	N/A
12/31/2018	N/A	-2	N/A	-2	N/A
9/30/2018	N/A	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von HOTH über der Sparquote liegt (3.5%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von HOTH schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von HOTH in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von HOTH schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von HOTH schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HOTH in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/21 03:29
Aktienkurs zum Tagesende	2026/05/21 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Hoth Therapeutics, Inc. wird von 1 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Jason Kolbert	D. Boral Capital LLC.

Hoth Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 14% to US$4.50

Price target decreased by 50% to US$9.50

Price target decreased to US$19.00

Price target decreased to US$3.00

Price target decreased to US$3.50

Forecast to breakeven in 2023

Recent updates

Hoth Therapeutics, Inc. Secures European Authorization In Spain For HT-001 Phase 2a Trial As Interim Data Show Strong Efficacy In Cancer Patients

Hoth Therapeutics, Inc. Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

Hoth Therapeutics Reports Positive Data for GDNF in Liver Fat Metabolism and Outperforms Semaglutide

New major risk - Shareholder dilution

Hoth Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

New minor risk - Share price stability

Hoth Therapeutics Announces Positive Clinical Results for HT-001 Program

Hoth Therapeutics Inc Deploys OpenClaw AI Platform to Accelerate Drug Discovery

Hoth Therapeutics Reports Positive HT-001 Pharmacokinetic, Safety, and Clinical Activity Data in Cancer Patients with EFGR Therapy-Associated Skin Toxicities

Hoth Therapeutics Reports Positive Female Preclinical Data Showing Ht-Va Restores Cholesterol Levels and Improves Lipid Metabolism in Masld Model

Hoth Therapeutics, Inc. Announces Significant Expansion of Its Cleer-001 Phase 2A Clinical Trial with the Addition of Regis Clinical Research as A New Enrolling Site

Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's Ht-Va Gdnf Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics, Inc. Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated Ht-Kit, Advancing Ht-001 Phase 2, and New Gdnf Metabolic Program

New major risk - Financial position

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rarec-KIT-Driven Cancers

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics, Inc. Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and Menin Inhibitor-Associated Skin Toxicities

Hoth Therapeutics, Inc. Announces Expansion of Phase II Clinical Trial Infrastructure

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

100% Patient Improvement in trial puts this $16M Biotech on the radar

Hoth Therapeutics Inc.'s Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones with Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

100% Patient Improvement in trial puts this $16M Biotech on the radar

Hoth Therapeutics HT-001 Interim Results First-In-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway

Hoth Therapeutics, Inc., Annual General Meeting, Aug 05, 2025

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Receives Notice of Delisting Due to Non-Compliance with Nasdaq Bid Price

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive Kit-Driven Cancers

Hoth Therapeutics Receives Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics, Inc. Announces Board and Committee Changes, Effective as of April 15, 2025

Hoth Therapeutics Announces Positive Initial Data in Phase 2A Clinical Trial

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease

New major risk - Financial position

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for Ht-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Regains Compliance with Nasdaq Listing Rules

Hoth Therapeutics, Inc. Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.7 million.

Hoth Therapeutics Notifies by the Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirements

Hoth Therapeutics, Inc. Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics, Inc. Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

New major risk - Share price stability

Price target decreased by 14% to US$4.50

New minor risk - Share price stability

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. Expands Clinical Trial for Cancer Patients

New major risk - Shareholder dilution

Hoth Therapeutics, Inc., Annual General Meeting, Aug 07, 2024

New major risk - Financial position

Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami

Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies

Hoth Therapeutics, Inc. Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

Price target decreased by 50% to US$9.50

Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

Hoth Therapeutics, Inc. Receives Protocol Approval for HT-001 Cancer Therapeutic

Hoth Therapeutics Announces Irb Approval for Fda Cleared First-In-Human Clinical Trial of Ht-001 At Second Clinical Site

New major risk - Share price stability

Hoth Therapeutics, Inc., Annual General Meeting, Aug 18, 2023